BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp. and served as chairman and CEO of Pfizer Inc. (NYSE:PFE) in 2006-10. Mission Therapeutics Ltd. promoted Paul...
BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

DISEASE CATEGORY: Neurology INDICATION: Fragile X syndrome An FMR1-based peptide therapy could treat Fragile X syndrome. The therapy comprises a FMR1 N-terminal fragment -- the first 297 residues -- conjugated to a cell-penetrating peptide derived...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inducing Golgi complex fragmentation by inhibiting the transcription factor KLF7 or the Golgi integrity maintenance factors DLG3 or STX5 could treat pancreatic ductal adenocarcinoma (PDAC). In pancreas samples from...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Hyaluronic acid, collagen to prevent intervertebral disc degeneration after herniation

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal An injectable therapy comprising hyaluronic acid and a high-density collagen patch could prevent acute intervertebral disc degeneration after herniation as well as subsequent discectomy. The strategy involves injecting a hexadecyl...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

Building on decades of work on a new mechanism, NoNO Inc. is laying the groundwork for an FDA approval in stroke, a notoriously difficult indication that hasn’t seen a new therapy in almost 25 years....
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

Century Therapeutics LLC appointed Joseph Jimenez, former CEO of Novartis AG (NYSE:NVS; SIX:NOVN), to its board. Jimenez retired in 2018 after eight years at the pharma’s helm, leading it through multiple patent expirations, business integrations...
BioCentury | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
Items per page:
1 - 10 of 292